J Korean Med Sci.  2009 Dec;24(6):1083-1088. 10.3346/jkms.2009.24.6.1083.

Gender Difference in the Prodromal Symptoms of First-episode Schizophrenia

• Choi JS
• Chon MW
• Kang DH
• Jung MH
• Kwon JS

• KMID: 1783137
• DOI: http://doi.org/10.3346/jkms.2009.24.6.1083

Abstract

To investigate the gender difference of early symptoms appearing before the onset of the psychotic symptoms in patients with first-episode schizophrenia, we reviewed the medical records of 63 patients (38 males, 25 females), who were hospitalized for first-episode schizophrenia. The frequency and duration of prodromal and psychotic symptoms, Clinical Global Impression scale scores, Global Assessment of Functioning (GAF) scale scores at admission, and other clinical characteristics were recorded for all patients. Overall, the most common prodromal symptoms were attenuated positive symptoms (89%), followed by mood symptoms (86%). Negative symptoms were the most common in male patients (97.4%), whereas attenuated positive symptoms were the most common in female patients (84%). Male patients demonstrated more frequent negative, cognitive, and obsessive-compulsive symptoms than female patients did and also showed a tendency of having negative symptoms for the longer period. Correlational analysis showed a significant negative correlation between the duration of negative symptoms and GAF scores at admission in male patients. Our findings suggest that different patterns of prodromal symptoms between male and female begin before the onset of the psychosis. Further prospective studies should be needed.

Keyword

Schizophrenia; First-episode Schizophrenia; Sex Factors; Prodrome of Schizophrenia

MeSH Terms

Adolescent
Adult
Age of Onset
Female
Humans
Male
Neuropsychological Tests
Psychiatric Status Rating Scales
Schizophrenia/diagnosis/*physiopathology
Sex Factors
Young Adult

Figure

• 

  Fig. 1 Frequency of early symptoms during the prodromal phase in patients with first-episode schizophrenia. *P<0.05 between male and female patients.

Reference

1. Jeppesen P, Petersen L, Thorup A, Abel MB, Ohlenschlaeger J, Christensen TO, Krarup G, Jorgensen P, Nordentoft M. The association between pre-morbid adjustment, duration of untreated psychosis and outcome in first-episode psychosis. Psychol Med. 2008. 38:1157–1166.

2. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005. 162:1785–1804.

3. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002. 59:921–928.

4. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res. 2004. 67:131–142.

5. Gourzis P, Katrivanou A, Beratis S. Symptomatology of the initial prodromal phase in schizophrenia. Schizophr Bull. 2002. 28:415–429.

6. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry. 1996. 30:587–599.

7. Goldstein J, Lewine R. Castle DJ, McGrath J, Kulkarni J, editors. Overview of sex differences in schizophrenia: Where have we been and where do we go from here? Women and Schizophrenia. 2000. Cambridge: Cambridge University Press;111–143.

8. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000. 401:3–38.

9. Goldstein JM. Sex, hormones and affective arousal circuitry dysfunction in schizophrenia. Horm Behav. 2006. 50:612–622.

10. Willhite RK, Niendam TA, Bearden CE, Zinberg J, O'Brien MP, Cannon TD. Gender differences in symptoms, functioning and social support in patients at ultra-high risk for developing a psychotic disorder. Schizophr Res. 2008. 104:237–245.

11. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008. 65:28–37.

12. Amminger GP, Leicester S, Yung AR, Phillips LJ, Berger GE, Francey SM, Yuen HP, McGorry PD. Early-onset of symptoms predicts conversion to non-affective psychosis in ultra-high risk individuals. Schizophr Res. 2006. 84:67–76.

13. Hafner H, Riecher-Rossler A, Hambrecht M, Maurer K, Meissner S, Schmidtke A, Fatkenheuer B, Loffler W, van der Heiden W. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. Schizophr Res. 1992. 6:209–223.

14. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003. 61:7–18.

15. Norman RM, Malla AK. Duration of untreated psychosis: a critical examination of the concept and its importance. Psychol Med. 2001. 31:381–400.

16. Bottlender R, Strauss A, Moller HJ. Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients. Schizophr Res. 2000. 44:145–150.

17. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003. 160:1396–1404.

18. Lappin JM, Dazzan P, Morgan K, Morgan C, Chitnis X, Suckling J, Fearon P, Jones PB, Leff J, Murray RM, McGuire PK. Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. Br J Psychiatry Suppl. 2007. 51:S123–S127.

19. Hafner H, Loffler W, Maurer K, Hambrecht M, an der Heiden W. Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand. 1999. 100:105–118.

20. Norman RM, Scholten DJ, Malla AK, Ballageer T. Early signs in schizophrenia spectrum disorders. J Nerv Ment Dis. 2005. 193:17–23.

21. Rosen JL, Miller TJ, D'Andrea JT, McGlashan TH, Woods SW. Comorbid diagnoses in patients meeting criteria for the schizophrenia prodrome. Schizophr Res. 2006. 85:124–131.

22. Svirskis T, Korkeila J, Heinimaa M, Huttunen J, Ilonen T, Ristkari T, McGlashan T, Salokangas RK. Axis-I disorders and vulnerability to psychosis. Schizophr Res. 2005. 75:439–446.

23. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry. 1993. 162:80–86.

24. Larsen TK, McGlashan TH, Moe LC. First-episode schizophrenia: I. Early course parameters. Schizophr Bull. 1996. 22:241–256.

25. Cohen RZ, Gotowiec A, Seeman MV. Duration of pretreatment phases in schizophrenia: women and men. Can J Psychiatry. 2000. 45:544–547.

26. Folnegovic Z, Folnegovic-Smalc V. Schizophrenia in Croatia: age of onset differences between males and females. Schizophr Res. 1994. 14:83–91.

27. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997. 51:535–541.

28. Pohjalainen T, Rinne JO, Nagren K, Lehikoinen P, Anttila K, Syvalahti EK, Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psychiatry. 1998. 3:256–260.

29. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003. 28:Suppl 2. 55–68.

30. Barbui C, Nose M, Bindman J, Schene A, Becker T, Mazzi MA, Kikkert M, Camara J, Born A, Tansella M. Sex differences in the subjective tolerability of antipsychotic drugs. J Clin Psychopharmacol. 2005. 25:521–526.